Pfizer muted in pharma sector comparison, shares trail S&P 500 peers

Pfizer in the S&P 500 pharma cohort shows a cautious profile, with the stock lagging sector peers and carrying a Hold consensus from Wall Street analysts.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 14:42.

Pfizer Inc. (US7170811035) sits in the large-cap pharma cohort of the S&P 500, with the shares trading on the NYSE under the ticker PFE. The stock currently shows muted momentum compared with several healthcare peers, while analysts maintain a Hold consensus on the name.

Where Pfizer stands among peers

Pfizer is classified in the pharmaceuticals sector and is a constituent of the S&P 500 and S&P 100 indices, placing it alongside names such as Johnson & Johnson, Merck and Bristol Myers Squibb in US large-cap healthcare. On MarketBeat, 20 Wall Street analysts covering Pfizer over the past 12 months assign the stock a consensus rating of Hold, with 6 Buys, 12 Holds and 2 Sells. This rating profile is more cautious than typical sector leaders that often carry a Buy-skewed consensus. The Hold stance reflects a balanced view on Pfizer’s risk-reward in comparison with broader pharma peers, which in many cases benefit from stronger near-term growth visibility.

Recent performance and valuation markers

Pfizer shares last closed at 24.28 US dollars on the NYSE on 2026-06-26, with a marginal move of -0.06 percent on the day according to MarketBeat data. In extended trading shortly after, the shares ticked up to around 24.30 dollars, indicating a broadly steady short-term picture. Yahoo Finance data show a previous close of 25.64 dollars, an intraday trading range between 25.47 and 25.83 dollars, and a 52-week range from 24.48 to 31.54 dollars, underscoring that the stock is currently trading nearer to the lower end of its one-year band. Pfizer’s market capitalization stands at roughly 144.7 billion dollars, which is sizeable but below some global pharma peers that exceed 200 billion dollars in equity value. The combination of low-20s share price levels and large-cap status positions Pfizer as a significant but not leading valuation benchmark in the US pharma space.

The products behind the Pfizer stock

Pfizer generates revenue through a broad portfolio of prescription medicines and vaccines, including well-known brands such as the pneumococcal vaccine Prevnar and various oncology and cardiovascular therapies. The company also co-developed the COVID-19 vaccine Comirnaty with BioNTech, which became a major global product during the pandemic phase. Its diversified pipeline across immunology, oncology and rare diseases helps underpin long-term cash flows, even as individual product cycles mature.

Where the Pfizer shares trade today

The Pfizer shares (US7170811035) most recently traded on the NYSE at 24.28 US dollars as of 2026-06-26, 15:59 Eastern Time.

Key data on the Pfizer shares

• Company: Pfizer Inc.
• ISIN: US7170811035
• WKN: 852009
• Ticker: PFE
• Trading venue: NYSE
• Price (as of 2026-06-26, 15:59): 24.28 USD
• Market cap: 144.68 billion USD (as of 2026-06-26)
• Sector / industry: Pharmaceuticals / Biotechnology
• Index membership: S&P 500, S&P 100
• Next earnings date: not officially scheduled

This text is for informational purposes only and does not contain investment advice, tax advice or a recommendation to buy or sell securities. All data are based on sources cited and may change over time.